المؤلفون: Odeh DM; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt., Allam HA; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt., Baselious F; Department of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther-University of Halle-Wittenberg, Halle (Saale), Germany., Mahmoud WR; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt., Odeh MM; Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa, Jordan., Ibrahim HS; Department of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther-University of Halle-Wittenberg, Halle (Saale), Germany.; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt., Abdel-Aziz HA; Department of Applied Organic Chemistry, National Research Center, Cairo, Dokki, Egypt., Mohammed ER; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

المصدر: Drug development research [Drug Dev Res] 2024 May; Vol. 85 (3), pp. e22193.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8204468 Publication Model: Print Cited Medium: Internet ISSN: 1098-2299 (Electronic) Linking ISSN: 02724391 NLM ISO Abbreviation: Drug Dev Res Subsets: MEDLINE

مواضيع طبية MeSH: Pyridinium Compounds*/pharmacology , Pyridinium Compounds*/chemistry , Indolizines*/pharmacology , Indolizines*/chemistry , Bridged Bicyclo Compounds, Heterocyclic*/pharmacology , Bridged Bicyclo Compounds, Heterocyclic*/chemistry , Drug Design* , Cyclic N-Oxides*/pharmacology , Cyclic N-Oxides*/chemistry , Protein Kinase Inhibitors*/pharmacology , Protein Kinase Inhibitors*/chemical synthesis , Protein Kinase Inhibitors*/chemistry , Molecular Docking Simulation* , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemical synthesis , Antineoplastic Agents*/chemistry, Humans ; Cell Line, Tumor ; Cyclin-Dependent Kinases/antagonists & inhibitors ; Structure-Activity Relationship ; Pyrimidines/pharmacology ; Pyrimidines/chemistry ; Drug Screening Assays, Antitumor ; Cyclin-Dependent Kinase 5/antagonists & inhibitors ; Cyclin-Dependent Kinase 5/metabolism ; Cyclin-Dependent Kinase 9/antagonists & inhibitors ; Cyclin-Dependent Kinase 9/metabolism